COVID-19 vaccine acceptance climbed from 75% in 2021 to 79% in 2022 in 23 countries representing nearly 60% of the global population, finds a survey published yesterday in Nature Medicine.
...
In eight countries, however, vaccine hesitancy increased (range, 1.0% in the United Kingdom to 21.1% in South Africa). And nearly 1 in 8 of all respondents (12.1%), particularly those aged 18 to 29 years, said they were hesitant to receive a booster dose (range, 1.1% in China to 28.9% in Russia).
A pair of new studies describe infection- and vaccine-conferred immunity against the SARS-CoV-2 Omicron variant, with one showing that vaccinated people have good protection against BA.5 subvariant reinfection for at least 8 months after infection, and the other finding that the vaccine is 46% and 70% effective against infection and hospitalization, respectively, in children.
A study today in Clinical Infectious Diseases finds that a third COVID-19 vaccine dose triggered a robust immune response, regardless of whether recipients had been infected more than 3 months earlier, but it didn't significantly increase antibody levels in those infected less than 3 months before.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/QWUUVMUU2ZK53JSBWUJGZYIGBI.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/24KJQCG5N5IT3JSPXN2TIVGSGE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/VDIWMKKHGFIM3BDDK4IHZRDY5U.jpg)
